乳腺癌转移性复发在PET/CT上表现为FAPI阴性而FDG高摄取
一名69岁乳腺癌女性因CA-15-3升高行18F-FDG PET/CT,显示颈部和纵隔多发高代谢淋巴结;同批FDG高摄取淋巴结在68Ga-FAPI-04 PET/CT上为FAPI阴性,锁骨上淋巴结活检证实乳腺癌转移。本病例提示评估转移时也应考虑68Ga-FAPI-04 PET/CT的假阴性发现。
要点
- 乳腺癌患者FDG高摄取淋巴结在68Ga-FAPI-04 PET/CT上可表现为FAPI阴性。
- 锁骨上淋巴结活检证实为乳腺癌转移。
- 评估转移时也应考虑68Ga-FAPI-04 PET/CT的假阴性发现。
核心结论
- 本病例提示在评估乳腺癌转移扩散时,也应考虑68Ga-FAPI-04 PET/CT的假阴性发现。
研究设计与样本
- 本文为个案报告,对象为一名69岁乳腺癌女性。
主要发现
- 患者因CA-15-3水平升高行18F-FDG PET/CT,显示颈部和纵隔多发高代谢淋巴结。
- 同批18F-FDG高摄取淋巴结在68Ga-FAPI-04 PET/CT上为FAPI阴性。
- 锁骨上淋巴结活检证实为乳腺癌转移。
临床怎么用
- 作者认为,近期报告关注FAPI PET在乳腺癌中的潜力,但本病例提示评估转移扩散时也应考虑68Ga-FAPI-04 PET/CT的假阴性发现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 69-year-old woman with breast cancer underwent 18 F-FDG PET/CT because of the increased CA-15-3 level. 18 F-FDG PET/CT showed multiple hypermetabolic lymph nodes (LNs) in the neck and mediastinum. The patient was also referred for 68 Ga-fibroblast activation protein inhibitor (FAPI) 04 PET/CT for further evaluation. However, 18 F-FDG-avid LNs were FAPI-negative on 68 Ga-FAPI-04 PET/CT. Supraclavicular LN biopsy confirmed the metastasis of breast cancer. Recent reports have focused on the potential of FAPI PET imaging in breast cancer; however, this case highlights that false-negative 68 Ga-FAPI-04-PET/CT findings should also be considered while evaluating metastatic spread.
引用
- Civan C, Has Simsek D, Isik EG, et al. FAPI-Negative FDG-Avid Metastatic Relapse of Breast Cancer on PET/CT. Clin Nucl Med. 2023. PMID: 37220240. doi:10.1097/RLU.0000000000004704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。